Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octenisan Decolonization in High-Risk Orthopedic Surgery (BALGDEC)
NCT05647252Phase 3Completed
- Sponsor
- University Hospital Balgrist
- Start
- Feb 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of octenidine in surgical site infection (SSI), sponsored by University Hospital Balgrist. Started Feb 2023; status: completed.
02
Drugs
octenidine
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT05647252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647252.